MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Business Wire2024-12-11

NEW YORK, December 11, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490786835?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d_P2riZxEDPBCqKf9Mr3UQ--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1e68c1c0a46398ca15e3901b491093b3","is_english":true,"pubTime":"2024-12-11 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490786835","market":"us","top_or_hot":-1,"title":"MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress","media":"Business Wire","content":"<div>\n<p>NEW YORK, December 11, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing novel product candidates ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mindmed-scientific-presentations-american-college-120000832.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mindmed-scientific-presentations-american-college-120000832.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, December 11, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing novel product candidates ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mindmed-scientific-presentations-american-college-120000832.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHH","symbol_name":"Park Ha Biological Technology Co. Ltd.","start_time":0,"source_url":"https://finance.yahoo.com/news/mindmed-scientific-presentations-american-college-120000832.html","article_id":"2490786835","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d_P2riZxEDPBCqKf9Mr3UQ--~B/aD00MDM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1e68c1c0a46398ca15e3901b491093b3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490786835","pubTimestamp":1733918400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NEW YORK, December 11, 2024----Mind Medicine  Inc. , , a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 , the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ.Title: Functional and sexual disability, and quality of life after one dose of MM120  in adults with generalized anxiety disorderFormat: PosterPresenter: Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed. Title: Rapid and durable response to a single dose of MM120  in generalized anxiety disorder: A dose-optimization studyFormat: PosterPresenter: Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed. Posters are available on MindMed’s Company website.MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our missio","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHH":"Park Ha Biological Technology Co. Ltd.","MNMD":"Mind Medicine (MindMed) Inc.","WRD":"文远知行","BK4117":"多元化保险","AFG":"美国金融集团有限公司","BK4547":"WSB热门概念","BK4107":"财产与意外伤害保险","BK4007":"制药"},"translate_title":"MindMed在美国神经精神药理学学院(ACNP)2024年大会上的科学演讲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AFG":1,"PHH":1,"WRD":1,"MNMD":0.9},"content_text":"NEW YORK, December 11, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the \"Company\" or \"MindMed\"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ.\nDetails of the presentations are as follows:\nTitle: Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with generalized anxiety disorderFormat: PosterPresenter: Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed\nTitle: Rapid and durable response to a single dose of MM120 (lysergide) in generalized anxiety disorder: A dose-optimization studyFormat: PosterPresenter: Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed\nPosters are available on MindMed’s Company website.\nAbout MindMed\nMindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.\nThis press release is not sanctioned by ACNP.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241211736280/en/\nContacts\nFor Media: media@mindmed.co For Investors: ir@mindmed.co For Medical Affairs: medaffairs@mindmed.co","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490786835"}